Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aecom (ACM) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

Amylx Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Aecom vs Amylx Pharmaceuticals Inc — how do they compare? Aecom trades at $62.83 (market cap $8.62B), while Amylx Pharmaceuticals Inc trades at $23.68 (market cap $2.64B). The key difference: Aecom is far larger — about 3.3× Amylx Pharmaceuticals Inc's market cap, and Aecom pays a 1.77% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

ACMAMLX
Market Cap
$8.62B$2.64B
Sector
IndustrialsHealth
52-Week High
$134.35$24.19
52-Week Low
$66.86$7.82
Enterprise Value
$10.81B$2.39B
Dividend Yield
1.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aecom

ACM's stock is trading at $73.30, down 3.35% in the last session, reflecting negative momentum after a Q2 2026 earnings miss. The technical outlook is bearish, with support at $72 and resistance at $76. Fundamentally, revenue reached $16.14 billion in 2025, but net income margin is thin at 1.87%, and ROE is negative. Recent news includes a securities investigation announcement and a large project charge impacting earnings.

The investment outlook is mixed: analyst consensus is bullish with a $88.25 price target, but risks include earnings volatility, a fraud probe, and rising debt-to-asset ratio. Opportunities lie in record backlog growth and new project wins like the Lisbon airport design. Investors should weigh strong institutional support against operational and legal headwinds.

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Returns comparison

Trailing returns across standard periods

About Aecom

Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.

Read more on ACM

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX